LBA
CABA icon

Letko, Brosseau & Associates’s Cabaletta Bio CABA Stock Holding History

Letko, Brosseau & Associates’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$281K Hold
90,475
– – ﹤0.01% 94
2026
Q1 		$243K Hold
90,475
– – ﹤0.01% 88
2025
Q4 		$198K Buy
+90,475
New +$224K ﹤0.01% 91

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Letko, Brosseau & Associates's CABA Position: Q2 2026 in Review

Letko, Brosseau & Associates held its Cabaletta Bio (CABA) position steady in Q2 2026 at 90,475 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #94.

Letko, Brosseau & Associates first reported a position in CABA in Q4 2025 and has held it in 3 quarters since. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Letko, Brosseau & Associates held 90,475 shares of Cabaletta Bio worth $281K as of Q2 2026.
  • Letko, Brosseau & Associates left its Cabaletta Bio share count unchanged in Q2 2026.
  • Cabaletta Bio made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #94 holding.
  • Letko, Brosseau & Associates first reported a position in Cabaletta Bio in Q4 2025 and has held it in 3 quarters since.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.